跳至主要内容
临床试验/NCT05589480
NCT05589480已完成不适用

Multimodal Data Prediction Based on Machine Learning for Recurrence Risk of Pancreatic Cancer After Radical Resection

Luo Cong1 个研究点 分布在 1 个国家目标入组 226 人开始时间: 2022年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
226
试验地点
1
主要终点
Recurrence-free survival

研究概览

简要总结

Recurrence of Pancreatic Cancer(PCa) is a multifactorial event. Based on the clinicopathological characteristics and imaging data of patients with PCa, the investigators used image processing and machine learning algorithms to build a more comprehensive and robust model, and added some unused features to explore its clinical application value.

A retrospective analysis of patients with PCa who underwent radical resection at Zhejiang Cancer Hospital (Hangzhou, China) from January 2013 to December 2020. The database was extracted from the preoperative demographics, blood markers, and surgical pathology information of patients undergoing radical PCa surgery in the investigators' hospital. The investigators used the PyRadiomics platform to extract image features.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Have the results of enhanced CT examination of the pancreas within 1 month before surgery in our hospital;
  • Radical resection of pancreatic cancer was performed in our hospital;
  • There are follow-up results in our hospital, and the follow-up endpoints include disease recurrence or at least 12 months.
  • Complete clinical medical records and imaging data.

排除标准

  • non-R0 resection;
  • Combined with other malignant tumors
  • The patient's imaging data has technical problems or the lesion is too small (less than 1cm), which is not suitable for omics analysis.

结局指标

主要结局

Recurrence-free survival

时间窗: 1 year

次要结局

未报告次要终点

研究者

发起方
Luo Cong
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Luo Cong

Deputy Director

Zhejiang Cancer Hospital

研究点 (1)

Loading locations...

相似试验

Machine Learning for Recurrence Risk of Pancreatic... | 临床试验